Roche focusing on fundamentals in a challenging environment
This article was originally published in Scrip
Despite increasing price pressure in major markets around the world, Roche says it will not change its principal long-term business strategy of focusing on what it is good at, namely science and innovation.
You may also be interested in...
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.